Form 8-K

8-K — LABCORP HOLDINGS INC.

Accession: 0000920148-26-000135

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000920148

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — lh-20260430.htm (Primary)

EX-99.1 (form8-kexhibit9911q26.htm)

GRAPHIC (labcorp_logoxhorizontalxco.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lh-20260430.htm · Sequence: 1

lh-20260430

0000920148false00009201482026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

April 30, 2026

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware 1-11353 99-2588107

(State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

358 South Main Street

Burlington , North Carolina 27215

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class Trading Symbol Name of exchange on which registered

Common Stock, $0.10 par value LH New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

Exhibit Exhibit Name

Exhibit 99.1

Press Release dated April 30, 2026 issued by Labcorp titled “Labcorp Announces 2026 First Quarter Results”

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant

Date: April 30, 2026 By: /s/ KATHRYN W. KYLE

Kathryn W. Kyle

Executive Vice President, Chief Legal Officer and Corporate Secretary

EX-99.1

Filename: form8-kexhibit9911q26.htm · Sequence: 2

Document

FOR IMMEDIATE RELEASE

Contact: Dewey Steadman - Investors Racquel White - Media

Investor@labcorp.com Media@labcorp.com

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

•Results from Operations for first quarter 2026 versus first quarter 2025:

◦Revenue: $3.54 billion vs. $3.35 billion, up 5.8%

◦Diluted EPS: $3.35 vs. $2.52, up 32.8%

◦Adjusted EPS: $4.25 vs. $3.84, up 10.6%

•Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:

◦Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint

◦Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint

•Advanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborations

•Collaborated with Optum.ai to enhance patient and provider experience

BURLINGTON, N.C., April 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2026 and updated full-year guidance.

“Labcorp delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our Diagnostics and Central Laboratory businesses,” said Adam Schechter, Chairman and CEO of Labcorp. “Health systems, providers, consumers, and biopharmaceutical customers are increasingly turning to Labcorp as their partner of choice for their complex, innovative testing needs. Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13.”

Labcorp continues to advance its strategic priorities:

Be a partner of choice for health systems and regional and local laboratories:

•Announced a nationwide strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients.

•Completed the acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs.

Lead in specialty testing:

•Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.

•Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum‑resistant ovarian cancer who may benefit from Merck’s KEYTRUDA® and KEYTRUDA QLEX™.

•Launched the Labcorp Fentanyl Visual Urine Test, an FDA‑cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours.

Shape our future through technology and innovation:

•Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s research.

•Expanded a collaboration with PathAI to deploy AISight® Dx, an FDA-cleared digital pathology platform.

•Announced a collaboration with Optum.ai to apply AI capabilities to streamline laboratory operations, improve efficiency, and enhance the patient and provider experience.

Drive personalized health solutions:

•Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men’s and women’s health tests.

•In May, the company will launch MyLabcorp, a secure, AI-powered mobile app that brings an individual’s test results and health data together with clinical guidance to help consumers better understand their test results.

Labcorp also remains committed to a disciplined allocation of capital. In the first quarter of 2026, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends. On April 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record at the close of business on May 29, 2026.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended March 31,

2026 2025 Delta

Revenue Summary (Dollars in billions)

Total Revenue $ 3.54 $ 3.35 5.8 %

Organic(1)

3.1 %

Acquisitions, net of Divestitures(2)

1.4 %

Foreign Exchange 1.3 %

(1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(2) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (Dollars in millions, except per share data)

Operating Income (“OI”) $ 380.8 $ 326.0

OI as % of Revenue 10.8 % 9.7 % 100 bps

Adjustments (3)

$ 127.1 $ 143.0

Adjusted Operating Income (“AOI”) (4)

$ 507.9

(5)

$ 469.0

AOI as % of Revenue 14.4 %

(5)

14.0 % 30 bps

Net Earnings Attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8

Diluted EPS $ 3.35 $ 2.52

Adjusted EPS (4)

$ 4.25 $ 3.84 10.6 %

(3) Adjustments include amortization, impairment charges, restructuring charges, and special items.

(4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(5) The increase in adjusted operating income and margin was primarily driven by organic growth.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended March 31,

2026 2025

Cash Flow Summary (Dollars in millions)

Operating Cash Flow $ 191.5 $ 18.5

Capital Expenditures 121.0 126.0

Free Cash Flow $ 70.5

(1)

$ (107.5)

(1) The increase in free cash flow was primarily driven by higher cash earnings.

Capital Allocation Summary

•At the end of the quarter, Labcorp's cash and cash equivalents balance was $981.1 million and total debt was $6.33 billion. These higher cash and debt balances are due to the pre-funding of maturing debt.

•During the quarter, the company invested $202.2 million in acquisitions, repurchased $98.0 million of stock, and paid out $61.2 million in dividends.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Diagnostics Laboratories Segment Summary

Three Months Ended March 31,

2026 2025 Delta

Revenue Summary (Dollars in billions)

Total Revenue $ 2.76 $ 2.63 5.0 %

Organic 2.9 %

Acquisitions, net of Divestitures 2.0 %

Foreign Exchange 0.2 %

Earnings Summary (1) (Dollars in millions)

Adjusted Operating Income (“AOI”) (2)

$ 458.7 (3) $ 427.5

AOI as % of Revenue 16.6 % (3) 16.3 % 30 bps

(1) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(3) Adjusted operating income and margin increased primarily driven by organic growth, despite the impact from adverse weather.

Three Months Ended March 31, 2026

Requisition Price/Mix

Volume Delta (4)

Delta (4)

Metrics Summary

Total 2.5 % 2.6 %

Organic (5)

1.1 % (6) 1.8 %

Acquisitions, net of Divestitures 1.4 % 0.6 %

Foreign Exchange — % 0.2 %

(4) Column shows changes versus the three months ended March 31, 2025.

(5) Organic price/mix includes lab management agreements.

(6) Includes the impact from adverse weather.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Biopharma Laboratory Services Segment Summary

Three Months Ended March 31,

2026 2025 Delta

Revenue Summary (Dollars in millions)

Total Revenue $ 780.6 $ 721.3 8.2 %

(1)

Organic(2)

3.7 %

Acquisitions, net of Divestitures(3)

(1.0) %

Foreign Exchange 5.5 %

(1) Central Labs revenue growth of 11.3% and Early Development revenue growth of 0.6%.

(2) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(3) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (4) (Dollars in millions)

Adjusted Operating Income (“AOI”) (5)

$ 120.7

(6)

$ 106.9

AOI as % of Revenue 15.5 %

(6)

14.8 % 60 bps

(4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(5) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(6) Adjusted Operating Income and margin increased driven by growth in Central Labs.

As of

March 31, 2026

Metrics Summary (Dollars in billions)

TTM Net Orders $ 3.29

TTM Book to Bill 1.04

Backlog $ 8.64

(7)

Next Twelve Months Forecast Backlog Conversion $ 2.69

(7) Backlog increased 5.6% compared to this period last year.

Guidance for 2026

Labcorp is updating 2026 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

(Dollars in billions, except per share data)

Previous Updated

2026 Guidance

Low High Low High

Revenue

Labcorp Enterprise (1)(2)

$14.61 $14.79 $14.65 $14.80

Growth (3)

4.7% 6.0% 5.0% 6.1%

Diagnostics Laboratories $11.42 $11.53 $11.43 $11.52

Growth (3)

5.0% 6.0% 5.1% 5.9%

Biopharma Laboratory Services (4)

$3.19 $3.25 $3.22 $3.27

Growth (3)

3.0% 5.0% 3.8% 5.4%

Adjusted EPS $17.55 $18.25 $17.70 $18.35

Free Cash Flow $1.24 $1.36 $1.24 $1.36

(1) 2026 Updated guidance includes an impact from foreign currency translation of 0.4%.

(2) Enterprise level revenue is presented net of intercompany transaction eliminations.

(3) Growth based on 2025 Enterprise revenue of $14.0 billion, Diagnostics revenue of $10.9 billion, and Biopharma Laboratory Services revenue of $3.1 billion.

(4) 2026 Updated guidance includes an impact from foreign currency translation of 1.5%.

Use of Adjusted Measures

The company has provided in this press release and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise “special items” used for certain adjusted financial information are included in the tables accompanying this press release.

The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.

A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the “Events” section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company’s former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company’s information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward- looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”.

- End of Text -

- Tables to Follow -

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Millions, Except Per Share Data)

Three Months Ended March 31,

2026 2025

Revenues $ 3,537.6 $ 3,345.1

Cost of revenues 2,523.8 2,397.1

Gross profit 1,013.8 948.0

Selling, general, and administrative expenses 551.0 546.0

Amortization of intangibles and other assets 75.6 69.6

Restructuring and other charges 6.4 6.4

Operating income 380.8 326.0

Other (expense) income:

Interest expense (55.1) (56.0)

Investment income 12.2 6.5

Equity method loss, net (5.1) (0.3)

Other, net (13.1) (1.0)

Earnings from operations before income taxes 319.7 275.2

Provision for income taxes 41.7 62.2

Net earnings 278.0 213.0

Less: Net earnings attributable to the noncontrolling interest (0.2) (0.2)

Net earnings attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8

Earnings per common share:

Basic earnings per common share $ 3.37 $ 2.54

Diluted earnings per common share $ 3.35 $ 2.52

Weighted-average basic common shares outstanding 82.3 83.6

Weighted-average diluted common shares outstanding 82.9 84.3

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Millions)

March 31, 2026 December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents $ 981.1 $ 532.3

Accounts receivable, net 2,288.6 2,103.8

Unbilled services, net 161.9 156.9

Supplies inventory 497.7 534.7

Prepaid expenses and other 629.5 692.8

Total current assets 4,558.8 4,020.5

Property, plant, and equipment, net 3,065.5 3,081.5

Goodwill, net 6,955.2 6,789.5

Intangible assets, net 3,636.1 3,596.0

Joint venture partnerships and equity method investments 146.6 153.9

Other assets, net 724.9 751.3

Total assets $ 19,087.1 $ 18,392.7

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Accounts payable $ 695.7 $ 840.8

Accrued expenses and other 851.9 847.8

Unearned revenue 405.2 439.1

Short-term operating lease liabilities 183.2 191.1

Short-term finance lease liabilities 4.6 4.6

Short-term borrowings and current portion of long-term debt 500.4 500.1

Total current liabilities 2,641.0 2,823.5

Long-term debt 5,833.7 5,084.6

Operating lease liabilities 656.5 682.6

Finance lease liabilities 62.2 63.0

Deferred income taxes and other tax liabilities 456.4 454.5

Other liabilities 691.8 647.8

Total liabilities 10,341.6 9,756.0

Commitments and contingent liabilities

Noncontrolling interest 16.9 16.9

Shareholders’ equity:

Common stock, 82.3 and 82.2 shares outstanding at March 31, 2026, and December 31, 2025, respectively 7.4 7.5

Additional paid-in capital — —

Retained earnings 8,784.4 8,639.9

Accumulated other comprehensive loss (63.2) (27.6)

Total shareholders’ equity 8,728.6 8,619.8

Total liabilities and shareholders’ equity $ 19,087.1 $ 18,392.7

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Millions)

Three Months Ended March 31,

2026 2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net earnings $ 278.0 $ 213.0

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization 173.3 166.8

Stock compensation 31.7 32.8

Operating lease right-of-use asset expense 48.0 48.6

Deferred income taxes 2.0 (6.1)

Other, net 11.4 8.1

Change in assets and liabilities (net of effects of acquisitions and divestitures):

Increase in accounts receivable (187.9) (170.8)

(Increase) decrease in unbilled services (6.2) 3.9

Decrease in supplies inventory 35.4 8.4

Decrease in prepaid expenses and other 4.0 45.0

Decrease in accounts payable (138.7) (147.6)

Decrease in unearned revenue (32.1) (8.9)

Decrease in accrued expenses and other (27.4) (174.7)

Net cash provided by operating activities 191.5 18.5

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures (121.0) (126.0)

Proceeds from sale of assets 7.8 0.5

Purchase of equity affiliates or other investments (6.7) (157.0)

Acquisition of businesses, net of cash acquired (202.2) (53.5)

Net cash used for investing activities (322.1) (336.0)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from term loan 750.0 —

Payments on senior notes — (1,000.0)

Proceeds from accounts receivable securitization — 225.0

Proceeds from revolving credit facilities — 64.8

Payments on revolving credit facilities — (64.8)

Net share settlement tax payments from issuance of stock to employees (39.8) (25.5)

Net proceeds from issuance of stock to employees 32.9 25.7

Dividends paid (61.2) (61.6)

Purchase of common stock (98.0) —

Other, net (3.4) (3.3)

Net cash provided by (used for) financing activities 580.5 (839.7)

Effect of exchange rate on changes in Cash and cash equivalents (1.1) 7.9

Net increase (decrease) in Cash and cash equivalents 448.8 (1,149.3)

Cash and cash equivalents at beginning of period 532.3 1,518.7

Cash and cash equivalents at end of period $ 981.1 $ 369.4

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Condensed Combined Non-GAAP Segment Information

(Dollars in Millions)

Three Months Ended March 31,

2026 2025

Diagnostics Laboratories

Revenues $ 2,762.1 $ 2,629.6

Adjusted operating income $ 458.7 $ 427.5

Adjusted operating margin 16.6 % 16.3 %

Biopharma Laboratory Services

Revenues $ 780.6 $ 721.3

Adjusted operating income $ 120.7 $ 106.9

Adjusted operating margin 15.5 % 14.8 %

Consolidated

Revenues $ 3,537.6 $ 3,345.1

Adjusted segment operating income $ 579.4 $ 534.4

Unallocated corporate expense (71.5) (65.4)

Consolidated adjusted operating income $ 507.9 $ 469.0

Adjusted operating margin 14.4 % 14.0 %

The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Measures

(Dollars and Shares in Millions, Except Per Share Data)

Three Months Ended March 31,

2026 2025

Adjusted Operating Income

Operating income $ 380.8 $ 326.0

Amortization of intangibles and other assets (a)

75.6 69.6

Restructuring and other charges (b)

6.4 6.4

Acquisition and disposition-related costs (c)

9.9 29.1

Launchpad costs (d)

13.0 20.1

Other 22.2 14.5

TSA reimbursement (e)

— 3.3

Adjusted operating income $ 507.9 $ 469.0

Adjusted operating profit margin 14.4 % 14.0 %

Adjusted Net Income

Net income $ 277.8 $ 212.8

Impact of adjustments to operating income 127.1 143.0

Loss on venture fund investments, net (f)

7.1 3.4

Equity method loss from SYNLAB investment (g)

5.0 —

TSA reimbursement (e)

— (3.3)

Other (8.5) —

Income tax impact of adjustments (h)

(56.1) (31.9)

Adjusted net income $ 352.4 $ 324.0

Weighted-average diluted common shares outstanding 82.9 84.3

Adjusted net income per share $ 4.25 $ 3.84

(a) Amortization of intangible assets acquired as part of business acquisitions.

(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.

(c) Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, and other integration or disposition related activities.

(d) LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.

(e) Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income.

(f) The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.

(g) Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.

(h) Income tax impact of adjustments calculated based on the tax rate applicable to each item.

GRAPHIC

Filename: labcorp_logoxhorizontalxco.jpg · Sequence: 6

Binary file (110565 bytes)

Download labcorp_logoxhorizontalxco.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover page

Apr. 30, 2026

Cover page. [Abstract]

Written Communications

false

Entity Address, Address Line One

358 South Main Street

Entity Tax Identification Number

99-2588107

Entity Central Index Key

0000920148

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

LABCORP HOLDINGS INC.

City Area Code

336

Local Phone Number

229-1127

Title of 12(b) Security

Common Stock, $0.10 par value

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

1-11353

Entity Address, City or Town

Burlington

Entity Address, State or Province

Entity Address, Postal Zip Code

27215

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Document Type

8-K

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Cover page. [Abstract]

+ References

No definition available.

+ Details

Name:

lh_Coverpage.Abstract

Namespace Prefix:

lh_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration